Skip to main content
SpringerLink
Log in

Depletion and Mutation of Topoisomerase II in Animal Cells

  • Protocol
  • First Online:
DNA Topoisomerases

Part of the book series: Methods in Molecular Biology™ ((MIMB,volume 582))

Abstract

Eukaryotic type II topoisomerases (Topo II) are implicated in a wide range of cellular processes. Cells in which Topo II protein has been specifically depleted or mutated provide powerful systems for analysing the normal in vivo functions of Topo II proteins and for assessing their roles in various chemotherapy regimens. Summarised here are the ways in which Topo II has been depleted or mutated in animal cells and the type of information gleaned. The cell lines generated are tabulated and represent a useful resource for further in vivo studies of Topo II function, one that we expect to grow in size and utility in the coming years.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Protocol
USD 49.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 84.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 149.00
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 109.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Austin, C. A. and Marsh, K. L. (1998) Eukaryotic DNA topoisomerase II beta. Bioessays 20, 215–226.

    Article  PubMed  CAS  Google Scholar 

  2. Gao, H., Huang, K. C., Yamasaki, E. F., Chan, K. K., Chohan, L. and Snapka, R. M. (1999) XK469, a selective topoisomerase IIbeta poison. Proceedings of the National Academy of Sciences of the United States of America 96, 12168–12173.

    Article  PubMed  CAS  Google Scholar 

  3. Toyoda, E., Kagaya, S., Cowell, I. G., Kurosawa, A., Kamoshita, K., Nishikawa, K., Iiizumi, S., Koyama, H., Austin, C. A. and Adachi, N. (2008) NK314, a topoisomerase II inhibitor that specifically targets the alpha isoform. The Journal of Biological Chemistry 283, 23711–23720.

    Article  PubMed  CAS  Google Scholar 

  4. Jensen, L. H., Dejligbjerg, M., Hansen, L. T., Grauslund, M., Jensen, P. B. and Sehested, M. (2004) Characterisation of cytotoxicity and DNA damage induced by the topoisomerase II-directed bisdioxopiperazine anti-cancer agent ICRF-187 (dexrazoxane) in yeast and mammalian cells. BMC Pharmacology 4, 31.

    Article  PubMed  Google Scholar 

  5. Oestergaard, V. H., Knudsen, B. R. and Andersen, A. H. (2004) Dissecting the cell-killing mechanism of the topoisomerase II-targeting drug ICRF-193. The Journal of Biological Chemistry 279, 28100–28105.

    Article  PubMed  CAS  Google Scholar 

  6. Gewirtz, D. A. (1999) A critical evaluation of the mechanisms of action proposed for the antitumor effects of the anthracycline antibiotics adriamycin and daunorubicin. Biochemical Pharmacology 57, 727–741.

    Article  PubMed  CAS  Google Scholar 

  7. Minotti, G., Menna, P., Salvatorelli, E., Cairo, G. and Gianni, L. (2004) Anthracyclines: molecular advances and pharmacologic developments in antitumor activity and cardiotoxicity. Pharmacological Reviews 56, 185–229.

    Article  PubMed  CAS  Google Scholar 

  8. DeChiara, T. M. (2001) Gene targeting in ES cells. Methods in Molecular Biology (Clifton, NJ) 158, 19–45.

    PubMed  CAS  Google Scholar 

  9. Caldwell, R. B., Fiedler, P., Schoetz, U. and Buerstedde, J. M. (2007) Gene function analysis using the chicken B-cell line DT40. Methods in Molecular Biology (Clifton, NJ) 408, 193–210.

    Article  PubMed  CAS  Google Scholar 

  10. Adachi, N., Kurosawa, A. and Koyama, H. (2008) Highly proficient gene targeting by homologous recombination in the human pre-B cell line Nalm-6. Methods in Molecular Biology (Clifton, NJ) 435, 17–29.

    Article  PubMed  CAS  Google Scholar 

  11. Feederle, R., Delecluse, H. J., Rouault, J. P., Schepers, A. and Hammerschmidt, W. (2004) Efficient somatic gene targeting in the lymphoid human cell line DG75. Gene 343, 91–97.

    Article  PubMed  CAS  Google Scholar 

  12. Adachi, N., Suzuki, H., Iiizumi, S. and Koyama, H. (2003) Hypersensitivity of nonhomologous DNA end-joining mutants to VP-16 and ICRF-193: implications for the repair of topoisomerase II-mediated DNA damage. The Journal of Biological Chemistry 278, 35897–35902.

    Article  PubMed  CAS  Google Scholar 

  13. Akimitsu, N., Adachi, N., Hirai, H., Hossain, M. S., Hamamoto, H., Kobayashi, M., Aratani, Y., Koyama, H. and Sekimizu, K. (2003) Enforced cytokinesis without complete nuclear division in embryonic cells depleting the activity of DNA topoisomerase IIalpha. Genes Cells 8, 393–402.

    Article  PubMed  CAS  Google Scholar 

  14. Yang, X., Li, W., Prescott, E. D., Burden, S. J. and Wang, J. C. (2000) DNA topoisomerase IIbeta and neural development. Science 287, 131–134.

    Article  PubMed  CAS  Google Scholar 

  15. Lyu, Y. L., Lin, C. P., Azarova, A. M., Cai, L., Wang, J. C. and Liu, L. F. (2006) Role of topoisomerase IIbeta in the expression of developmentally regulated genes. Molecular and Cellular Biology 26, 7929–7941.

    Article  PubMed  CAS  Google Scholar 

  16. Nur, E. K. A., Meiners, S., Ahmed, I., Azarova, A., Lin, C. P., Lyu, Y. L. and Liu, L. F. (2007) Role of DNA topoisomerase IIbeta in neurite outgrowth. Brain Research 1154, 50–60.

    Article  Google Scholar 

  17. Azarova, A. M., Lyu, Y. L., Lin, C. P., Tsai, Y. C., Lau, J. Y., Wang, J. C. and Liu, L. F. (2007) Roles of DNA topoisomerase II isozymes in chemotherapy and secondary malignancies. Proceedings of the National Academy of Sciences of the United States of America 104, 11014–11019.

    Article  PubMed  CAS  Google Scholar 

  18. Errington, F., Willmore, E., Tilby, M. J., Li, L., Li, G., Li, W., Baguley, B. C. and Austin, C. A. (1999) Murine transgenic cells lacking DNA topoisomerase IIbeta are resistant to acridines and mitoxantrone: analysis of cytotoxicity and cleavable complex formation. Molecular Pharmacology 56, 1309–1316.

    PubMed  CAS  Google Scholar 

  19. Lyu, Y. L., Kerrigan, J. E., Lin, C. P., Azarova, A. M., Tsai, Y. C., Ban, Y. and Liu, L. F. (2007) Topoisomerase IIbeta mediated DNA double-strand breaks: implications in doxorubicin cardiotoxicity and prevention by dexrazoxane. Cancer Research 67, 8839–8846.

    Article  PubMed  CAS  Google Scholar 

  20. Zhang, A., Lyu, Y. L., Lin, C. P., Zhou, N., Azarova, A. M., Wood, L. M. and Liu, L. F. (2006) A protease pathway for the repair of topoisomerase II-DNA covalent complexes. The Journal of Biological Chemistry 281, 35997–36003.

    Article  PubMed  CAS  Google Scholar 

  21. Wessel, I., Jensen, L. H., Renodon-Corniere, A., Sorensen, T. K., Nitiss, J. L., Jensen, P. B. and Sehested, M. (2002) Human small cell lung cancer NYH cells resistant to the bisdioxopiperazine ICRF-187 exhibit a functional dominant Tyr165Ser mutation in the Walker A ATP binding site of topoisomerase II alpha. FEBS Letters 520, 161–166.

    Article  PubMed  CAS  Google Scholar 

  22. Grauslund, M., Thougaard, A. V., Fuchtbauer, A., Hofland, K. F., Hjorth, P. H., Jensen, P. B., Sehested, M., Fuchtbauer, E. M. and Jensen, L. H. (2007) A mouse model for studying the interaction of bisdioxopiperazines with topoisomerase IIalpha in vivo. Molecular Pharmacology 72, 1003–1014.

    Article  PubMed  CAS  Google Scholar 

  23. Carpenter, A. J. and Porter, A. C. (2004) Construction, characterization, and complementation of a conditional-lethal DNA topoisomerase IIalpha mutant human cell line. Molecular Biology of the Cell 15, 5700–5711.

    Article  PubMed  CAS  Google Scholar 

  24. Bridewell, D. J., Porter, A. C., Finlay, G. J. and Baguley, B. C. (2008) The role of topoisomerases and RNA transcription in the action of the antitumour benzonaphthyridine derivative SN 28049. Cancer Chemotherapy and Pharmacology 62, 753–762.

    Article  PubMed  CAS  Google Scholar 

  25. Zhang, X. D., Goeres, J., Zhang, H., Yen, T. J., Porter, A. C. and Matunis, M. J. (2008) SUMO-2/3 modification and binding regulate the association of CENP-E with kinetochores and progression through mitosis. Molecular Cell 29, 729–741.

    Article  PubMed  CAS  Google Scholar 

  26. Linka, R. M., Porter, A. C., Volkov, A., Mielke, C., Boege, F. and Christensen, M. O. (2007) C-terminal regions of topoisomerase IIalpha and IIbeta determine isoform-specific functioning of the enzymes in vivo. Nucleic Acids Research 35, 3810–3822.

    Article  PubMed  CAS  Google Scholar 

  27. Kobayashi, M., Adachi, N., Aratani, Y., Kikuchi, A. and Koyama, H. (2001) Decreased topoisomerase IIalpha expression confers increased resistance to ICRF-193 as well as VP-16 in mouse embryonic stem cells. Cancer Letters 166, 71–77.

    Article  PubMed  CAS  Google Scholar 

  28. Yamazoe, M., Sonoda, E., Hochegger, H. and Takeda, S. (2004) Reverse genetic studies of the DNA damage response in the chicken B lymphocyte line DT40. DNA Repair 3, 1175–1185.

    Article  PubMed  CAS  Google Scholar 

  29. Burgess, D. J., Doles, J., Zender, L., Xue, W., Ma, B., McCombie, W. R., Hannon, G. J., Lowe, S. W. and Hemann, M. T. (2008) Topoisomerase levels determine chemotherapy response in vitro and in vivo. Proceedings of the National Academy of Sciences of the United States of America 105, 9053–9058.

    Article  PubMed  Google Scholar 

  30. Sakaguchi, A. and Kikuchi, A. (2004) Functional compatibility between isoform alpha and beta of type II DNA topoisomerase. Journal of Cell Science 117, 1047–1054.

    Article  PubMed  CAS  Google Scholar 

  31. Spence, J. M., Phua, H. H., Mills, W., Carpenter, A. J., Porter, A. C. and Farr, C. J. (2007) Depletion of topoisomerase IIalpha leads to shortening of the metaphase interkinetochore distance and abnormal persistence of PICH-coated anaphase threads. Journal of Cell Science 120, 3952–3964.

    Article  PubMed  CAS  Google Scholar 

  32. Chang, C. J., Goulding, S., Earnshaw, W. C. and Carmena, M. (2003) RNAi analysis reveals an unexpected role for topoisomerase II in chromosome arm congression to a metaphase plate. Journal of Cell Science 116, 4715–4726.

    Article  PubMed  CAS  Google Scholar 

  33. Coelho, P. A., Queiroz-Machado, J., Carmo, A. M., Moutinho-Pereira, S., Maiato, H. and Sunkel, C. E. (2008) Dual role of topoisomerase II in centromere resolution and aurora B activity. PLoS Biology 6, e207.

    Article  PubMed  Google Scholar 

  34. Savvidou, E., Cobbe, N., Steffensen, S., Cotterill, S. and Heck, M. M. (2005) Drosophila CAP-D2 is required for condensin complex stability and resolution of sister chromatids. Journal of Cell Science 118, 2529–2543.

    Article  PubMed  CAS  Google Scholar 

  35. Tsang, W. P., Kong, S. K. and Kwok, T. T. (2006) Epidermal growth factor induction of resistance to topoisomerase II toxins in human squamous carcinoma A431 cells. Oncology Reports 16, 789–793.

    PubMed  CAS  Google Scholar 

  36. Emmons, M., Boulware, D., Sullivan, D. M. and Hazlehurst, L. A. (2006) Topoisomerase II beta levels are a determinant of melphalan-induced DNA crosslinks and sensitivity to cell death. Biochemical Pharmacology 72, 11–18.

    Article  PubMed  CAS  Google Scholar 

  37. Mandraju, R. K., Kannapiran, P. and Kondapi, A. K. (2008) Distinct roles of Topoisomerase II isoforms: DNA damage accelerating alpha, double strand break repair promoting beta. Archives of Biochemistry and Biophysics 470, 27–34.

    Article  PubMed  CAS  Google Scholar 

  38. Marchion, D. C., Bicaku, E., Turner, J. G., Daud, A. I., Sullivan, D. M. and Munster, P. N. (2005) Synergistic interaction between histone deacetylase and topoisomerase II inhibitors is mediated through topoisomerase IIbeta. Clinical Cancer Research 11, 8467–8475.

    Article  PubMed  CAS  Google Scholar 

  39. Feldhoff, P. W., Mirski, S. E., Cole, S. P. and Sullivan, D. M. (1994) Altered subcellular distribution of topoisomerase II alpha in a drug-resistant human small cell lung cancer cell line. Cancer Research 54, 756–762.

    PubMed  CAS  Google Scholar 

  40. Wessel, I., Jensen, P. B., Falck, J., Mirski, S. E., Cole, S. P. and Sehested, M. (1997) Loss of amino acids 1490Lys-Ser-Lys1492 in the COOH-terminal region of topoisomerase IIalpha in human small cell lung cancer cells selected for resistance to etoposide results in an extranuclear enzyme localization. Cancer Research 57, 4451–4454.

    PubMed  CAS  Google Scholar 

  41. Eder, J. P., Jr., Chan, V. T., Niemierko, E., Teicher, B. A. and Schnipper, L. E. (1993) Conditional expression of wild-type topoisomerase II complements a mutant enzyme in mammalian cells. The Journal of Biological Chemistry 268, 13844–13849.

    PubMed  CAS  Google Scholar 

  42. McPherson, J. P., Deffie, A. M., Jones, N. R., Brown, G. A., Deuchars, K. L. and Goldenberg, G. J. (1997) Selective sensitization of adriamycin-resistant P388 murine leukemia cells to antineoplastic agents following transfection with human DNA topoisomerase II alpha. Anticancer Research 17, 4243–4252.

    PubMed  CAS  Google Scholar 

  43. Hsiung, Y., Jannatipour, M., Rose, A., McMahon, J., Duncan, D. and Nitiss, J. L. (1996) Functional expression of human topoisomerase II alpha in yeast: mutations at amino acids 450 or 803 of topoisomerase II alpha result in enzymes that can confer resistance to anti-topoisomerase II agents. Cancer Research 56, 91–99.

    PubMed  CAS  Google Scholar 

  44. Sehested, M., Wessel, I., Jensen, L. H., Holm, B., Oliveri, R. S., Kenwrick, S., Creighton, A. M., Nitiss, J. L. and Jensen, P. B. (1998) Chinese hamster ovary cells resistant to the topoisomerase II catalytic inhibitor ICRF-159: a Tyr49Phe mutation confers high-level resistance to bisdioxopiperazines. Cancer Research 58, 1460–1468.

    PubMed  CAS  Google Scholar 

  45. Leontiou, C., Lakey, J. H. and Austin, C. A. (2004) Mutation E522K in human DNA topoisomerase IIbeta confers resistance to methyl N-(4′-(9-acridinylamino)-phenyl) carbamate hydrochloride and methyl N-(4′-(9-acridinylamino)-3-methoxy-phenyl) methane sulfonamide but hypersensitivity to etoposide. Molecular Pharmacology 66, 430–439.

    PubMed  CAS  Google Scholar 

  46. Akimitsu, N., Kamura, K., Tone, S., Sakaguchi, A., Kikuchi, A., Hamamoto, H. and Sekimizu, K. (2003) Induction of apoptosis by depletion of DNA topoisomerase IIalpha in mammalian cells. Biochemical and Biophysical Research Communications 307, 301–307.

    Article  PubMed  CAS  Google Scholar 

  47. McNamara, S., Wang, H., Hanna, N. and Miller, W. H., Jr. (2008) Topoisomerase IIbeta negatively modulates retinoic acid receptor alpha function: a novel mechanism of retinoic acid resistance. Molecular and Cellular Biology 28, 2066–2077.

    Article  PubMed  CAS  Google Scholar 

  48. Son, Y. S., Suh, J. M., Ahn, S. H., Kim, J. C., Yi, J. Y., Hur, K. C., Hong, W. S., Muller, M. T. and Chung, I. K. (1998) Reduced activity of topoisomerase II in an Adriamycin-resistant human stomach-adenocarcinoma cell line. Cancer Chemotherapy and Pharmacology 41, 353–360.

    Article  PubMed  CAS  Google Scholar 

  49. McPherson, J. P., Brown, G. A. and Goldenberg, G. J. (1993) Characterization of a DNA topoisomerase IIalpha gene rearrangement in adriamycin-resistant P388 leukemia: expression of a fusion messenger RNA transcript encoding topoisomerase IIalpha and the retinoic acid receptor alpha locus. Cancer Research 53, 5885–5889.

    PubMed  CAS  Google Scholar 

  50. Herzog, C. E., Holmes, K. A., Tuschong, L. M., Ganapathi, R. and Zwelling, L. A. (1998) Absence of topoisomerase IIbeta in an amsacrine-resistant human leukemia cell line with mutant topoisomerase IIalpha. Cancer Research 58, 5298–5300.

    PubMed  CAS  Google Scholar 

  51. Bakic, M., Beran, M., Andersson, B. S., Silberman, L., Estey, E. and Zwelling, L. A. (1986) The production of topoisomerase II-mediated DNA cleavage in human leukemia cells predicts their susceptibility to 4′-(9-acridinylamino)methanesulfon-m-anisidide (m-AMSA). Biochemical and Biophysical Research Communications 134, 638–645.

    Article  PubMed  CAS  Google Scholar 

  52. Hinds, M., Deisseroth, K., Mayes, J., Altschuler, E., Jansen, R., Ledley, F. D. and Zwelling, L. A. (1991) Identification of a point mutation in the topoisomerase II gene from a human leukemia cell line containing an amsacrine-resistant form of topoisomerase II. Cancer Research 51, 4729–4731.

    PubMed  CAS  Google Scholar 

  53. Lee, M. S., Wang, J. C. and Beran, M. (1992) Two independent amsacrine-resistant human myeloid leukemia cell lines share an identical point mutation in the 170 kDa form of human topoisomerase II. Journal of Molecular Biology 223, 837–843.

    Article  PubMed  CAS  Google Scholar 

  54. Mayes, J., Hinds, M., Soares, L., Altschuler, E., Kim, P. and Zwelling, L. A. (1993) Further characterization of an amsacrine-resistant line of HL-60 human leukemia cells and its topoisomerase II. Effects of ATP concentration, anion concentration, and the three-dimensional structure of the DNA target. Biochemical Pharmacology 46, 699–707.

    Article  PubMed  CAS  Google Scholar 

  55. Odaimi, M., Andersson, B. S., McCredie, K. B. and Beran, M. (1986) Drug sensitivity and cross-resistance of the 4′-(9-acridinylamino)methanesulfon-m-anisidide-resistant subline of HL-60 human leukemia. Cancer Research 46, 3330–3333.

    PubMed  CAS  Google Scholar 

  56. Matsumoto, Y., Takano, H., Kunishio, K., Nagao, S. and Fojo, T. (2001) Incidence of mutation and deletion in topoisomerase II alpha mRNA of etoposide and mAMSA-resistant cell lines. Japanese Journal of Cancer Research 92, 1133–1137.

    Article  PubMed  CAS  Google Scholar 

  57. Dereuddre, S., Delaporte, C. and Jacquemin-Sablon, A. (1997) Role of topoisomerase II beta in the resistance of 9-OH-ellipticine-resistant Chinese hamster fibroblasts to topoisomerase II inhibitors. Cancer Research 57, 4301–4308.

    PubMed  CAS  Google Scholar 

  58. Dereuddre, S., Frey, S., Delaporte, C. and Jacquemin-Sablon, A. (1995) Cloning and characterization of full-length cDNAs coding for the DNA topoisomerase II beta from Chinese hamster lung cells sensitive and resistant 9-OH-ellipticine. Biochimica et Biophysica Acta 1264, 178–182.

    Article  PubMed  Google Scholar 

  59. Salles, B., Charcosset, J. Y. and Jacquemin-Sablon, A. (1982) Isolation and properties of Chinese hamster lung cells resistant to ellipticine derivatives. Cancer Treatment Reports 66, 327–338.

    PubMed  CAS  Google Scholar 

  60. Saxena, D., Yiu, G. K., Ni, X., Huang, K. C., Mantovani, R., Jacquemin-Sablon, A. G. and Ng, S. W. (2004) Characterization of promoter elements involved in the down-regulation of topoisomerase IIalpha expression in a drug-resistant cell line. Gene 342, 145–155.

    Article  PubMed  CAS  Google Scholar 

  61. Grue, P., Grasser, A., Sehested, M., Jensen, P. B., Uhse, A., Straub, T., Ness, W. and Boege, F. (1998) Essential mitotic functions of DNA topoisomerase IIalpha are not adopted by topoisomerase IIbeta in human H69 cells. The Journal of Biological Chemistry 273, 33660–33666.

    Article  PubMed  CAS  Google Scholar 

  62. Jensen, P. B., Christensen, I. J., Sehested, M., Hansen, H. H. and Vindelov, L. (1993) Differential cytotoxicity of 19 anticancer agents in wild type and etoposide resistant small cell lung cancer cell lines. British Journal of Cancer 67, 311–320.

    Article  PubMed  CAS  Google Scholar 

  63. Mirski, S. E. and Cole, S. P. (1995) Cytoplasmic localization of a mutant M(r) 160,000 topoisomerase II alpha is associated with the loss of putative bipartite nuclear localization signals in a drug-resistant human lung cancer cell line. Cancer Research 55, 2129–2134.

    PubMed  CAS  Google Scholar 

  64. Mirski, S. E., Evans, C. D., Almquist, K. C., Slovak, M. L. and Cole, S. P. (1993) Altered topoisomerase II alpha in a drug-resistant small cell lung cancer cell line selected in VP-16. Cancer Research 53, 4866–4873.

    PubMed  CAS  Google Scholar 

  65. Mirski, S. E., Sparks, K. E., Yu, Q., Lang, A. J., Jain, N., Campling, B. G. and Cole, S. P. (2000) A truncated cytoplasmic topoisomerase IIalpha in a drug-resistant lung cancer cell line is encoded by a TOP2A allele with a partial deletion of exon 34. International Journal of Cancer 85, 534–539.

    Article  CAS  Google Scholar 

  66. Yu, Q., Mirski, S. E., Sparks, K. E. and Cole, S. P. (1997) Two COOH-terminal truncated cytoplasmic forms of topoisomerase II alpha in a VP-16-selected lung cancer cell line result from partial gene deletion and alternative splicing. Biochemistry 36, 5868–5877.

    Article  PubMed  CAS  Google Scholar 

  67. Patel, S. and Fisher, L. M. (1993) Novel selection and genetic characterisation of an etoposide-resistant human leukaemic CCRF-CEM cell line. British Journal of Cancer 67, 456–463.

    Article  PubMed  CAS  Google Scholar 

  68. Campain, J. A., Gottesman, M. M. and Pastan, I. (1994) A novel mutant topoisomerase II alpha present in VP-16-resistant human melanoma cell lines has a deletion of alanine 429. Biochemistry 33, 11327–11332.

    Article  PubMed  CAS  Google Scholar 

  69. Campain, J. A., Slovak, M. L., Schoenlein, P. V., Popescu, N. C., Gottesman, M. M. and Pastan, I. (1995) Acquisition of multiple copies of a mutant topoisomerase IIalpha allele by chromosome 17 aneuploidy is associated with etoposide resistance in human melanoma cell lines. Somatic Cell and Molecular Genetics 21, 451–471.

    Article  PubMed  CAS  Google Scholar 

  70. Kubo, A., Yoshikawa, A., Hirashima, T., Masuda, N., Takada, M., Takahara, J., Fukuoka, M. and Nakagawa, K. (1996) Point mutations of the topoisomerase IIalpha gene in patients with small cell lung cancer treated with etoposide. Cancer Research 56, 1232–1236.

    PubMed  CAS  Google Scholar 

  71. Jain, N., Lam, Y. M., Pym, J. and Campling, B. G. (1996) Mechanisms of resistance of human small cell lung cancer lines selected in VP-16 and cisplatin. Cancer 77, 1797–1808.

    Article  PubMed  CAS  Google Scholar 

  72. Kawanami, K., Nakamura, T., Ono, M., Kusano, T., Okada, K., Kikuchi, A., Adachi, N., Kohno, K., Higashi, K. and Kuwano, M. (1996) Decreased DNA topoisomerase II alpha expression and cold-sensitive growth in a mouse mammary cancer cell line resistant to etoposide and doxorubicin. Oncology Research 8, 197–206.

    PubMed  CAS  Google Scholar 

  73. Takano, H., Ise, T., Nomoto, M., Kato, K., Murakami, T., Ohmori, H., Imamura, T., Nagatani, G., Okamoto, T., Ohta, R., Furukawa, M., Shibao, K., Izumi, H., Kuwano, M. and Kohno, K. (1999) Structural and functional analysis of the control region of the human DNA topoisomerase II alpha gene in drug-resistant cells. Anti-Cancer Drug Design 14, 87–92.

    PubMed  CAS  Google Scholar 

  74. Fattman, C. L., Allan, W. P., Hasinoff, B. B. and Yalowich, J. C. (1996) Collateral sensitivity to the bisdioxopiperazine dexrazoxane (ICRF-187) in etoposide (VP-16)-resistant human leukemia K562 cells. Biochemical Pharmacology 52, 635–642.

    Article  PubMed  CAS  Google Scholar 

  75. Ritke, M. K., Roberts, D., Allan, W. P., Raymond, J., Bergoltz, V. V. and Yalowich, J. C. (1994) Altered stability of etoposide-induced topoisomerase II-DNA complexes in resistant human leukaemia K562 cells. British Journal of Cancer 69, 687–697.

    Article  PubMed  CAS  Google Scholar 

  76. Ritke, M. K. and Yalowich, J. C. (1993) Altered gene expression in human leukemia K562 cells selected for resistance to etoposide. Biochemical Pharmacology 46, 2007–2020.

    Article  PubMed  CAS  Google Scholar 

  77. Saleem, A., Ibrahim, N., Patel, M., Li, X. G., Gupta, E., Mendoza, J., Pantazis, P. and Rubin, E. H. (1997) Mechanisms of resistance in a human cell line exposed to sequential topoisomerase poisoning. Cancer Research 57, 5100–5106.

    PubMed  CAS  Google Scholar 

  78. Chan, V. T., Ng, S. W., Eder, J. P. and Schnipper, L. E. (1993) Molecular cloning and identification of a point mutation in the topoisomerase II cDNA from an etoposide-resistant Chinese hamster ovary cell line. The Journal of Biological Chemistry 268, 2160–2165.

    PubMed  CAS  Google Scholar 

  79. de Lucio, B., Manuel, V. and Barrera-Rodriguez, R. (2005) Characterization of human NSCLC cell line with innate etoposide-resistance mediated by cytoplasmic localization of topoisomerase II alpha. Cancer Science 96, 774–783.

    Article  PubMed  Google Scholar 

  80. Kubo, T., Kohno, K., Ohga, T., Taniguchi, K., Kawanami, K., Wada, M. and Kuwano, M. (1995) DNA topoisomerase II alpha gene expression under transcriptional control in etoposide/teniposide-resistant human cancer cells. Cancer Research 55, 3860–3864.

    PubMed  CAS  Google Scholar 

  81. Harker, W. G., Slade, D. L., Dalton, W. S., Meltzer, P. S. and Trent, J. M. (1989) Multidrug resistance in mitoxantrone-selected HL-60 leukemia cells in the absence of P-glycoprotein overexpression. Cancer Research 49, 4542–4549.

    PubMed  CAS  Google Scholar 

  82. Harker, W. G., Slade, D. L., Drake, F. H. and Parr, R. L. (1991) Mitoxantrone resistance in HL-60 leukemia cells: reduced nuclear topoisomerase II catalytic activity and drug-induced DNA cleavage in association with reduced expression of the topoisomerase II beta isoform. Biochemistry 30, 9953–9961.

    Article  PubMed  CAS  Google Scholar 

  83. Harker, W. G., Slade, D. L., Parr, R. L., Feldhoff, P. W., Sullivan, D. M. and Holguin, M. H. (1995) Alterations in the topoisomerase II alpha gene, messenger RNA, and subcellular protein distribution as well as reduced expression of the DNA topoisomerase II beta enzyme in a mitoxantrone-resistant HL-60 human leukemia cell line. Cancer Research 55, 1707–1716.

    PubMed  CAS  Google Scholar 

  84. Harker, W. G., Slade, D. L., Parr, R. L. and Holguin, M. H. (1995) Selective use of an alternative stop codon and polyadenylation signal within intron sequences leads to a truncated topoisomerase II alpha messenger RNA and protein in human HL-60 leukemia cells selected for resistance to mitoxantrone. Cancer Research 55, 4962–4971.

    PubMed  CAS  Google Scholar 

  85. Hazlehurst, L. A., Foley, N. E., Gleason-Guzman, M. C., Hacker, M. P., Cress, A. E., Greenberger, L. W., De Jong, M. C. and Dalton, W. S. (1999) Multiple mechanisms confer drug resistance to mitoxantrone in the human 8226 myeloma cell line. Cancer Research 59, 1021–1028.

    PubMed  CAS  Google Scholar 

  86. Bugg, B. Y., Danks, M. K., Beck, W. T. and Suttle, D. P. (1991) Expression of a mutant DNA topoisomerase II in CCRF-CEM human leukemic cells selected for resistance to teniposide. Proceedings of the National Academy of Sciences of the United States of America 88, 7654–7658.

    Article  PubMed  CAS  Google Scholar 

  87. Danks, M. K., Schmidt, C. A., Cirtain, M. C., Suttle, D. P. and Beck, W. T. (1988) Altered catalytic activity of and DNA cleavage by DNA topoisomerase II from human leukemic cells selected for resistance to VM-26. Biochemistry 27, 8861–8869.

    Article  PubMed  CAS  Google Scholar 

  88. Danks, M. K., Warmoth, M. R., Friche, E., Granzen, B., Bugg, B. Y., Harker, W. G., Zwelling, L. A., Futscher, B. W., Suttle, D. P. and Beck, W. T. (1993) Single-strand conformational polymorphism analysis of the M(r) 170,000 isozyme of DNA topoisomerase II in human tumor cells. Cancer Research 53, 1373–1379.

    PubMed  CAS  Google Scholar 

  89. Mao, Y., Yu, C., Hsieh, T. S., Nitiss, J. L., Liu, A. A., Wang, H. and Liu, L. F. (1999) Mutations of human topoisomerase II alpha affecting multidrug resistance and sensitivity. Biochemistry 38, 10793–10800.

    Article  PubMed  CAS  Google Scholar 

  90. Morgan, S. E. and Beck, W. T. (2001) Role of an inverted CCAAT element in human topoisomerase IIalpha gene expression in ICRF-187-sensitive and -resistant CEM leukemic cells. Molecular Pharmacology 59, 203–211.

    PubMed  CAS  Google Scholar 

  91. Morgan, S. E., Cadena, R. S., Raimondi, S. C. and Beck, W. T. (2000) Selection of human leukemic CEM cells for resistance to the DNA topoisomerase II catalytic inhibitor ICRF-187 results in increased levels of topoisomerase IIalpha and altered G(2)/M checkpoint and apoptotic responses. Molecular Pharmacology 57, 296–307.

    PubMed  CAS  Google Scholar 

  92. Wessel, I., Jensen, L. H., Jensen, P. B., Falck, J., Rose, A., Roerth, M., Nitiss, J. L. and Sehested, M. (1999) Human small cell lung cancer NYH cells selected for resistance to the bisdioxopiperazine topoisomerase II catalytic inhibitor ICRF-187 demonstrate a functional R162Q mutation in the Walker A consensus ATP binding domain of the alpha isoform. Cancer Research 59, 3442–3450.

    PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Haematology, Imperial College Faculty of Medicine, London, UK

    Andrew C.G. Porter

Authors
  1. Andrew C.G. Porter
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Dept. Genetics, Cell Biology &, University of Minnesota Medical School, Washington Ave. SE. 420, Minneapolis, 55455, U.S.A.

    Duncan J. Clarke

Rights and permissions

Reprints and permissions

Copyright information

© 2009 Humana Press, a part of Springer Science+Business Media, LLC

About this protocol

Cite this protocol

Porter, A.C. (2009). Depletion and Mutation of Topoisomerase II in Animal Cells. In: Clarke, D. (eds) DNA Topoisomerases. Methods in Molecular Biology™, vol 582. Humana Press, Totowa, NJ. https://doi.org/10.1007/978-1-60761-340-4_19

Download citation

  • DOI: https://doi.org/10.1007/978-1-60761-340-4_19

  • Published:

  • Publisher Name: Humana Press, Totowa, NJ

  • Print ISBN: 978-1-60761-339-8

  • Online ISBN: 978-1-60761-340-4

  • eBook Packages: Springer Protocols

Publish with us

Policies and ethics

Search

Navigation